Biogen (BIIB) PT Raised to $390 at Bernstein
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $225.71 +3.33%
Rating Summary:
29 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
29 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Bernstein analyst Aaron Gal raised the price target on Biogen (NASDAQ: BIIB) to $390.00 (from $370.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CCB Int'l Starts Biogen (BIIB) at Outperform
- Inmobiliaria Colonial Socimi SA (COL:SM) PT Lowered to EUR4.20 at Goldman Sachs
- Vonovia SE (VNA:DR) (VNNVF) PT Lowered to EUR18.40 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Sanford C. BernsteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
